ZEISS Announces Successful Early Implantations of AT LUCIA Toric 721P Intraocular Lens for Cataract and Astigmatism Correction
核心洞察
ZEISS Medical Technology reports successful early clinical implantations of the AT LUCIA toric 721P intraocular lens across six European countries, with surgeons describing it as a potential "game changer" for refractive outcomes.
The lens features an aspheric bitoric optic with a patented non-constant aberration design (ZO optic) on a fully preloaded, hydrophobic c-Loop platform, targeting both cataracts and astigmatism (搜索) simultaneously.
Early surgeon feedback highlights the lens's outstanding rotational stability, precision, ease of implantation, and consistent visual outcomes compared with other toric IOLs.
ZEISS Medical Technology announced on June 11, 2026, the successful early clinical implantations of the ZEISS AT LUCIA toric 721P (搜索) intraocular lens (IOL), a next-generation device engineered to treat cataracts while simultaneously correcting astigmatism (搜索). The announcement, made from the company's headquarters in Jena, Germany, marks a significant advancement in refractive cataract (搜索) surgery.
The new IOL combines an aspheric bitoric optic with a patented non-constant aberration design, termed ZO optic, mounted on a fully preloaded, hydrophobic c-Loop platform. This architecture is designed to deliver excellent visual outcomes and long-term stability for patients.
Early-Access Clinical Trial Underway Across Europe
ZEISS is currently conducting an early-access clinical trial with a select group of highly experienced surgeons from six European countries: the Czech Republic, Germany, Italy, Spain, Sweden, and the United Kingdom. Surgeons who have begun implanting the new lens have already reported positive early impressions.
"The overwhelmingly positive feedback we've received from surgeons strongly validates our optics leadership in the IOL market. The ZEISS AT LUCIA toric 721P (搜索) raises the bar for precision, stability, and ultimately positive surgical outcomes. This is a new era for IOL technology and ZEISS is at the forefront," said Frank Seitzinger, Head of Business Sector Surgery Anterior Segment at ZEISS Medical Technology.
Surgeon Testimonials Highlight Rotational Stability and Visual Quality
Dr. Andrea Janeková, Ph.D., FEBO, FEBOS-CR, Head of the Center for Cataract (搜索), Refractive and Vitreoretinal Surgery at Eye Center Prague, Czech Republic, was the first surgeon worldwide to implant the lens. "Being the first surgeon worldwide to implant the ZEISS AT LUCIA toric 721P (搜索) was a privilege. The lens combines precision, stability and excellent surgical handling. And in modern cataract surgery, precision matters more than ever. Based on my first experience, the ZEISS AT LUCIA toric 721P has all the ingredients of a true game changer for refractive outcomes," she stated.
Dr. Helena Noguera, MD, from the Department of Refractive and Phaco-Refractive Surgery at Miranza COI Bilbao and Galdácano-Usansolo University Hospital in Spain, emphasized the lens's comparative advantages. "Compared with other toric IOLs, the main advantages of the ZEISS AT LUCIA toric 721P (搜索) are its platform, its bitoric design, and its outstanding rotational stability. I expect this lens to enhance the predictability of refractive outcomes in my practice. Its proven platform gives me confidence in achieving reliable visual results for my patients."
Prof. Sathish Srinivasan, FRCSEd, FRCOphth, FACS, FWCRS, FEBOS-CR (Hon), Founder and Medical Director of Ayrshire Eye Clinic in Scotland, UK, noted the optical design benefits: "Based on my early experience, the ZEISS AT LUCIA toric 721P (搜索) with a non-constant aspheric profile truly enhances the quality of vision for patients. The step-vaulted profile and enhanced haptic-optic junction improves the rotational stability of this new toric IOL."
Dr. Amin-Robert Kassem, Chief Physician and Clinic Owner at Värnamo Eye Center in Sweden, added: "The ZEISS AT LUCIA toric 721P (搜索) stands out for its stability, ease of implantation, and consistent visual outcomes, which have been impressive in my initial experience. I expect this lens to expand our treatment options and help more patients achieve excellent vision with greater confidence and satisfaction."
Regulatory Status and Market Availability
The ZEISS AT LUCIA toric 721P (搜索) IOL will first be showcased at the International Congress of German Ophthalmic Surgery (DOC) in Nuremberg, Germany, from June 18 to 20, 2026. The lens is currently CE marked and is expected to become commercially available in select European countries later in 2026.
ZEISS Medical Technology, a segment of Carl Zeiss Meditec AG — listed on the TecDAX and SDAX of the German stock exchange — is one of the world's leading medical technology companies. The Group generated revenue of €2,228 million in fiscal year 2024/25 and employs 5,784 people worldwide. The company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases.